EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
176 hedge funds and large institutions have $802M invested in Eagle Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 73 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
4% less funds holding
Funds holding: 183 → 176 (-7)
25% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 73
Holders
176
Holding in Top 10
3
Calls
$15.4M
Puts
$5.04M
Top Buyers
| 1 | +$8.88M | |
| 2 | +$7.23M | |
| 3 | +$4.97M | |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$4.72M |
| 5 |
Goldman Sachs
New York
|
+$4.22M |
Top Sellers
| 1 | -$8.92M | |
| 2 | -$5.55M | |
| 3 | -$4.49M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.93M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.92M |